Teva Accupril Generic Delayed Until 2007; Pfizer Patent Is Valid, Court Says
This article was originally published in The Pink Sheet Daily
Executive Summary
If upheld on appeal, the decision would eliminate Teva’s 180-day exclusivity period and make a challenge to Pfizer’s own generic moot. A New Jersey federal judge finds there was no inequitable conduct before the PTO regarding Pfizer’s patent for its ACE inhibitor.
You may also be interested in...
Pfizer’s Accupril Patent Case Against Teva Heads Back To Court
A Newark, N.J. federal judge must reconsider whether an Accupril patent is valid and is infringed by Teva’s quinapril generic, an appeals court says.
Pfizer’s Accupril Patent Case Against Teva Heads Back To Court
A Newark, N.J. federal judge must reconsider whether an Accupril patent is valid and is infringed by Teva’s quinapril generic, an appeals court says.
Accupril Generics Come Off The Market Following Preliminary Injunction
Teva and Ranbaxy plan to appeal the district court ruling in favor of Pfizer to the federal appeals court. Pfizer said it will seek damages for lost Accupril sales since the December launch of Teva/Ranbaxy’s quinapril.